CLINICAL TRIALS

MOMENTUM STUDY: Efficacy and Safety of Pemvidutide in the Treatment of Obesity

STATUS: Ongoing

For more information

This study will evaluate the efficacy and safety of ALT-801 once-weekly versus placebo as an adjunct to a reduced-calorie diet and increased physical activity in patients with obesity/overweight.

Interim data on approximately 160 subjects expected Q1 2023.

Pemvidutide in Diabetic and Non-Diabetic Overweight and Obese Subjects with Non-alcoholic Fatty Liver Disease (NAFLD)

STATUS: Completed

For more information

The purpose of the study is to assess the safety and tolerability of ALT-801 in diabetic and non-diabetic overweight and obese subjects with non-alcoholic fatty liver disease (NAFLD).

12-wk NAFLD trial data announced Sep 2022.

Extension Trial of Pemvidutide in Diabetic and Non-Diabetic Overweight and Obese Subjects with Non-alcoholic Fatty Liver Disease (NAFLD)

STATUS: Ongoing

For more information

This extension study of the Phase 1 NAFLD study will enroll subjects who have completed 12 weeks of treatment in Study ALT-801-105. It is designed to allow for an additional 12 weeks of treatment in order to assess the safety and effects of 24 weeks of treatment with ALT-801 in diabetic and non-diabetic overweight and obese subjects with non-alcoholic fatty liver disease (NAFLD).

Data readout expected in Q4 2022.